Literature DB >> 16506206

The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer.

Cristina Bilbao1, Germán Rodríguez, Raquel Ramírez, Orlando Falcón, Laureano León, Ricardo Chirino, Juan F Rivero, Orlando Falcón, B Nicolás Díaz-Chico, Juan C Díaz-Chico, Manuel Perucho.   

Abstract

Microsatellite instability (MSI) and mutations in the PTEN gene are among the molecular alterations involved in endometrial carcinogenesis. There is conflicting information regarding to their role in this type of tumor. For this reason, we have studied both molecular lesions in a large population-based series of 205 patients with sporadic endometrial cancer. MSI was found in 41 (20.0%) of the tumors and PTEN mutations were found in 74 (36.1%). There were differences in genotype between tumors with and without MSI. Tumors with MSI showed both a higher frequency of PTEN mutations (58.5% vs. 30.4%) (p=0.002, Fisher's exact test) and a higher number of insertions or deletions (I/D) of one nucleotide within the mononucleotide tracts of the PTEN gene (45.8% vs. 11.4% out of all I/D, p=0.005). Conversely, G:C to A:T transitions in CpG dinucleotides were found mostly in microsatellite stable tumors (57.7% vs. 18.2% out of all single-base substitutions, p=0.037). Overall, 67.6% of tumors with mutated PTEN exhibited multiple mutations or allelic imbalance (AI). Multiple PTEN mutations in the same tumor were more frequent in tumors with MSI (60% vs. 25.7%); by contrast the presence of AI accompanying PTEN mutation was higher in microsatellite stable tumors (74.3% vs. 40%) (p=0.028). In addition, patients with both genetic alterations were diagnosed at more advanced stage of progression (54.2% for MSI vs. 20.0% for MSS, p=0.006), and exhibited a worse prognosis (hazard ratio [95% confidence interval]: 3.0 [1.1-13.1], p=0.034, log-rank test) than patients with only the PTEN gene mutated. Our data suggest that the DNA mismatch repair system status influences: (i) both the frequency and the mutational spectrum of PTEN; (ii) the nature of one of the hits that inactivate this tumor-suppressor gene; and (iii) the clinical condition and behavior of the patients. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16506206     DOI: 10.1002/ijc.21862

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

Review 2.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

3.  The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.

Authors:  K Shoji; K Oda; S Nakagawa; S Hosokawa; G Nagae; Y Uehara; K Sone; Y Miyamoto; H Hiraike; O Hiraike-Wada; T Nei; K Kawana; H Kuramoto; H Aburatani; T Yano; Y Taketani
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

4.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

5.  RhoA and RhoC -siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway.

Authors:  Hua-Wen Sun; Shi-Lun Tong; Jie He; Qi Wang; Li Zou; Shu-Jing Ma; Hai-Yan Tan; Jian-Fei Luo; Hong-Xue Wu
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

6.  Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer.

Authors:  L M Kuroki; M Mangano; J E Allsworth; C O Menias; L S Massad; M A Powell; D G Mutch; P H Thaker
Journal:  Ann Surg Oncol       Date:  2014-09-05       Impact factor: 5.344

Review 7.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

8.  Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer.

Authors:  Cristina Bilbao-Sieyro; Raquel Ramírez; Germán Rodríguez-González; Orlando Falcón; Laureano León; Santiago Torres; Leandro Fernández; Sergio Alonso; Nicolás Díaz-Chico; Manuel Perucho; Juan Carlos Díaz-Chico
Journal:  Oncotarget       Date:  2014-08-15

Review 9.  Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Authors:  David Barrett; Valerie I Brown; Stephan A Grupp; David T Teachey
Journal:  Paediatr Drugs       Date:  2012-10-01       Impact factor: 3.930

10.  Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.

Authors:  Bojana Djordjevic; Bedia A Barkoh; Rajyalakshmi Luthra; Russell R Broaddus
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.